I-SPY

I-SPY
Name	I-SPY
Type	Clinical trial consortium
Founded	2006
Founder	US Food and Drug Administration; QuantumLeap Healthcare Collaborative; National Cancer Institute
Headquarters	Boston, Massachusetts
Focus	Adaptive platform trials in breast cancer

I-SPY is an adaptive, multi-institutional clinical trial platform launched to accelerate evaluation of novel therapies in high-risk breast cancer. It was created to link consortia of academic centers, industry partners, regulatory agencies, and patient advocates to test multiple investigational agents concurrently using biomarker-driven subtyping, adaptive randomization, and pathologic complete response endpoints. The platform aims to shorten drug development timelines by integrating molecular profiling, imaging, and statistical learning across studies involving partners such as the National Cancer Institute, US Food and Drug Administration, and major academic cancer centers.

Background and Origins

I-SPY began as a collaborative effort among investigators at Dana–Farber Cancer Institute, Brigham and Women's Hospital, and University of California, San Francisco with support from the National Cancer Institute and input from the US Food and Drug Administration. Early pilot work built on precedents like the Breast International Group and lessons from landmark trials such as NSABP B-31 and BCIRG-006. The initiative was informed by precision oncology movements exemplified by projects including The Cancer Genome Atlas and consortia like Cancer Research UK and European Organisation for Research and Treatment of Cancer. Founders sought to overcome limitations seen in traditional phase II/III pipelines exemplified by large randomized trials at institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Study Design and Methodology

The platform uses an adaptive, Bayesian framework influenced by trial designs such as those from the I-SPY 1 pilot and innovations in adaptive randomization used in oncology consortia like STAMPEDE and BATTLE. Patients are stratified using biomarker panels developed in collaboration with groups including Foundation Medicine, Myriad Genetics, and academic laboratories at Fred Hutchinson Cancer Research Center. Imaging modalities such as dynamic contrast-enhanced magnetic resonance imaging performed at centers like Mayo Clinic and Cleveland Clinic are incorporated. Statistical oversight involves experts formerly associated with Harvard School of Public Health and Johns Hopkins Bloomberg School of Public Health, with regulatory consultation from the US Food and Drug Administration.

Clinical Trials and Therapeutic Findings

I-SPY has evaluated combinations including targeted agents from companies such as Genentech, Pfizer, Novartis, AstraZeneca, and GlaxoSmithKline, alongside standard neoadjuvant chemotherapy paradigms similar to regimens tested in NSABP trials. Notable investigational agents studied in the platform include antibody–drug conjugates and PARP inhibitors similar to drugs developed by Seattle Genetics and Clovis Oncology. Outcomes emphasized pathologic complete response, an endpoint validated in meta-analyses from groups like Early Breast Cancer Trialists' Collaborative Group. Results from the platform influenced subsequent phase III trials at centers such as Vanderbilt University Medical Center and pharmaceutical-sponsored registrational pathways reviewed by the European Medicines Agency and US Food and Drug Administration.

Biomarkers and Imaging Integration

The consortium integrated genomic assays modeled after panels from The Cancer Genome Atlas and companies like Illumina, using expression signatures related to HER2, hormone receptor status, and immune infiltration akin to biomarkers studied at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center. Circulating tumor DNA analyses leveraged methods developed in part by researchers at University of Cambridge and Stanford University School of Medicine. Imaging biomarkers used quantitative MRI metrics and PET imaging approaches similar to work at University College London and University of Toronto. These integrated data streams enabled adaptive enrichment strategies reminiscent of precision-medicine trials at MD Anderson Cancer Center.

Impact on Precision Oncology and Implementation

I-SPY's design contributed to broader acceptance of adaptive platform trials within regulatory and academic communities, inspiring initiatives at organizations like Translational Research Institute-affiliated centers and influencing policy discussions at the US Food and Drug Administration and European Medicines Agency. The platform informed curricula at institutions such as Harvard Medical School and Yale School of Medicine and contributed to cooperative group science in networks including the Alliance for Clinical Trials in Oncology and Gynecologic Oncology Group. Pharmaceutical sponsors including Roche and Eli Lilly and Company have used platform-derived signals to prioritize assets, and several academic centers implemented similar biomarker-driven neoadjuvant studies.

Criticisms, Limitations, and Controversies

Critiques have focused on generalizability of pathologic complete response surrogacy as debated by authors from Oxford University and meta-analyses by the Early Breast Cancer Trialists' Collaborative Group, and on complexities of adaptive statistics discussed at meetings of the American Society of Clinical Oncology and European Society for Medical Oncology. Concerns were raised about operational complexity at imaging core labs used by institutions like Mayo Clinic and data harmonization issues highlighted by researchers at Johns Hopkins University. Industry stakeholders such as Pfizer and Novartis debated trial prioritization, while patient advocates from groups like Susan G. Komen pressed for clarity on access and consent processes. Implementation challenges in community settings similar to those faced by Community Oncology Alliance clinics remain an ongoing issue.

Category:Clinical trials